Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short-term Investments: 2016-2021

Historic Short-term Investments for Aytu Biopharma (AYTU) over the last 5 years, with Sep 2021 value amounting to $252,000.

  • Aytu Biopharma's Short-term Investments changed negligibly% to $252,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $252,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $252,000 for FY2021, which is 0.40% up from last year.
  • Latest data reveals that Aytu Biopharma reported Short-term Investments of $252,000 as of Q3 2021, which was down 0.00% from $252,000 recorded in Q2 2021.
  • In the past 5 years, Aytu Biopharma's Short-term Investments registered a high of $252,000 during Q3 2020, and its lowest value of $75,214 during Q2 2017.
  • In the last 3 years, Aytu Biopharma's Short-term Investments had a median value of $251,698 in 2019 and averaged $236,269.
  • As far as peak fluctuations go, Aytu Biopharma's Short-term Investments tumbled by 92.78% in 2017, and later soared by 150.83% in 2019.
  • Aytu Biopharma's Short-term Investments (Quarterly) stood at $75,214 in 2017, then skyrocketed by 32.95% to $100,225 in 2018, then spiked by 150.83% to $251,396 in 2019, then rose by 0.24% to $252,000 in 2020, then remained steady at $252,000 in 2021.
  • Its last three reported values are $252,000 in Q3 2021, $252,000 for Q2 2021, and $252,000 during Q1 2021.